Cyanophyta Aphanizomenon Flos-aquae, and Adipose Stroma Vascular Fraction, in Heart Failure Patient

NCT ID: NCT04515537

Last Updated: 2023-01-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

15 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-20

Study Completion Date

2023-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a prospective, randomized, controlled trial to assess the efficacy of transplantation of autologous stroma vauscultar fraction and/or AFA in 15 patients with ischemic heart failure

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Stem cells therapy may be a choice therapy for advanced heart failure patients refractory to medical therapy, and a previous history of coronary artery diseases. In this study the investigators have evaluated consecutive 15 selected patients, the amelioration in failing heart NYHA class, hospitalization rate, echocardiographic left ventricle functionality, serum of Natriuretic peptide level and associated to reduction of angina after a treatment with stroma vascular fraction infusion y/or Stemregen capsule per oral.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congestive Heart Failure Chronic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

conventional therapy plus AFA

Patient using conventional therapy plus Extract of the Cyanophyta Aphanizomenon Flos-aquae (AFA), for a period of 6 months

Water-soluble Extract of the Cyanophyta Aphanizomenon Flos-aquae (AFA),

Intervention Type DIETARY_SUPPLEMENT

Patient use 2 capsules 3 time a day by oral.

conventional therapy plus SVF

Patient using conventional therapy plus aplication of stroma vascular fraction (SVF) from the adipose tissue, evaluted for period of 6 months

Infiltrtion of SVf

Intervention Type PROCEDURE

After filling up the informed consent Mini liposuction is performed under local anesthesia with klein solution, about 70 cc of dry fat tissue is suctioned and collagenase digestion is done with final centrifugation to obtain the SVF

conventional therapy plus SVF and AFA

Patient using conventional therapy plus aplication of stroma vascular fraction (SVF) from the adipose tissue plus Extract of the Cyanophyta Aphanizomenon Flos-aquae (AFA), for a period of 6 months

Water-soluble Extract of the Cyanophyta Aphanizomenon Flos-aquae (AFA),

Intervention Type DIETARY_SUPPLEMENT

Patient use 2 capsules 3 time a day by oral.

Infiltrtion of SVf

Intervention Type PROCEDURE

After filling up the informed consent Mini liposuction is performed under local anesthesia with klein solution, about 70 cc of dry fat tissue is suctioned and collagenase digestion is done with final centrifugation to obtain the SVF

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Water-soluble Extract of the Cyanophyta Aphanizomenon Flos-aquae (AFA),

Patient use 2 capsules 3 time a day by oral.

Intervention Type DIETARY_SUPPLEMENT

Infiltrtion of SVf

After filling up the informed consent Mini liposuction is performed under local anesthesia with klein solution, about 70 cc of dry fat tissue is suctioned and collagenase digestion is done with final centrifugation to obtain the SVF

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* EF \< 45 %
* NYHA 2 - 3

Exclusion Criteria

* Acute coronary syndrome within last 6 weeks.
* Pregnancy
* FEV1 \<20 %
* Cancer
* Any severe disease which could interfere with the treatment or the outcome
* Patient with immunodeficiency
* Candidate who are judged to be not applicable to this study by doctors.
Minimum Eligible Age

35 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Clinica Castello 68

OTHER

Sponsor Role collaborator

Sociedad Española de Medicina Regenerativa y Terapia Celular

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Miguel G Garber, MD

Role: PRINCIPAL_INVESTIGATOR

Healthy Longevity Clinic

Christian Drapeau, PhD

Role: STUDY_DIRECTOR

Kalyagen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinca Castello 68

Madrid, , Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Miguel G Garber, MD

Role: CONTACT

34 628766753

Felix Pedrero, MD

Role: CONTACT

34 622411766

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Miguel G Garber, MD

Role: primary

34 628766753

Felix Pedrero, MD

Role: backup

34 622411766

References

Explore related publications, articles, or registry entries linked to this study.

Sheu JJ, Lee MS, Wallace CG, Chen KH, Sung PH, Chua S, Lee FY, Chung SY, Chen YL, Li YC, Yip HK. Therapeutic effects of adipose derived fresh stromal vascular fraction-containing stem cells versus cultured adipose derived mesenchymal stem cells on rescuing heart function in rat after acute myocardial infarction. Am J Transl Res. 2019 Jan 15;11(1):67-86. eCollection 2019.

Reference Type BACKGROUND
PMID: 30787970 (View on PubMed)

Premaratne GU, Ma LP, Fujita M, Lin X, Bollano E, Fu M. Stromal vascular fraction transplantation as an alternative therapy for ischemic heart failure: anti-inflammatory role. J Cardiothorac Surg. 2011 Mar 31;6:43. doi: 10.1186/1749-8090-6-43.

Reference Type BACKGROUND
PMID: 21453457 (View on PubMed)

Kelm NQ, Beare JE, Yuan F, George M, Shofner CM, Keller BB, Hoying JB, LeBlanc AJ. Adipose-derived cells improve left ventricular diastolic function and increase microvascular perfusion in advanced age. PLoS One. 2018 Aug 24;13(8):e0202934. doi: 10.1371/journal.pone.0202934. eCollection 2018.

Reference Type BACKGROUND
PMID: 30142193 (View on PubMed)

Leblanc AJ, Nguyen QT, Touroo JS, Aird AL, Chang RC, Ng CK, Hoying JB, Williams SK. Adipose-derived cell construct stabilizes heart function and increases microvascular perfusion in an established infarct. Stem Cells Transl Med. 2013 Nov;2(11):896-905. doi: 10.5966/sctm.2013-0046. Epub 2013 Oct 8.

Reference Type BACKGROUND
PMID: 24106337 (View on PubMed)

Jensen GS, Hart AN, Zaske LA, Drapeau C, Gupta N, Schaeffer DJ, Cruickshank JA. Mobilization of human CD34+ CD133+ and CD34+ CD133(-) stem cells in vivo by consumption of an extract from Aphanizomenon flos-aquae--related to modulation of CXCR4 expression by an L-selectin ligand? Cardiovasc Revasc Med. 2007 Jul-Sep;8(3):189-202. doi: 10.1016/j.carrev.2007.03.004.

Reference Type BACKGROUND
PMID: 17765649 (View on PubMed)

Hart AN, Zaske LA, Patterson KM, Drapeau C, Jensen GS. Natural killer cell activation and modulation of chemokine receptor profile in vitro by an extract from the cyanophyta Aphanizomenon flos-aquae. J Med Food. 2007 Sep;10(3):435-41. doi: 10.1089/jmf.2007.401.

Reference Type BACKGROUND
PMID: 17887936 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

13245

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cardiovascular Metabolic Remodeling in Shock
NCT06285513 NOT_YET_RECRUITING
Fontan-Sprechstunde
NCT05563376 RECRUITING NA